Association of a Single-Nucleotide Variant rs11100494 of the <i>NPY5R</i> Gene with Antipsychotic-Induced Metabolic Disorders

Background: The usage of antipsychotics (APs) is the most robust and scientifically based approach in the treatment of schizophrenia spectrum disorders (SSDs). The efficiency of APs is based on a range of target receptors of the central nervous system (CNS): serotoninergic, dopaminergic, adrenergic,...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Vera S. Dobrodeeva, Natalia A. Shnayder, Maxim A. Novitsky, Azat R. Asadullin, Elena E. Vaiman, Marina M. Petrova, Oleg V. Limankin, Nikolay G. Neznanov, Natalia P. Garganeeva, Regina F. Nasyrova
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2022-01-01
Rangatū:	Pharmaceutics
Ngā marau:	pharmacogenetics schizophrenia NPYR neuropeptide Y receptor antipsychotic-induced weight gain adverse drug reactions
Urunga tuihono:	https://www.mdpi.com/1999-4923/14/2/222
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!